![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
KALA BIO Inc | NASDAQ:KALA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.07 | 6.75 | 7.35 | 0 | 12:00:03 |
By Stephen Nakrosis
Shares of Kala Pharmaceuticals Inc. were trading higher after-hours Monday, after the company said it entered into a definitive agreement for private-placement financing that could generate $31 million, and also submitted an application for an investigational new drug, or IND.
At 5:06 p.m. ET, the company's stock had risen 19.72% to trade at $6.65 per share. The stock had finished the day's regular session with a 1.92% loss, closing at $5.63 per share.
The private-placement deal with a life sciences-focused investor will see Kala sell shares of its common stock and Series E Convertible Non-Redeemable Preferred Stock in two tranches, for gross proceeds of up to $31 million, the company said.
Kala seperately said it has submitted an IND application with the U.S. Food and Drug Administration for KPI-012. The drug aims to treat Persistent Corneal Epithelial Defect, a condition which can lead to vision loss.
Subject to FDA acceptance of the IND, the company said it is on-track to initiate a Phase 2b clinical trial of KPI-012 this quarter.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 28, 2022 17:24 ET (22:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year KALA BIO Chart |
1 Month KALA BIO Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions